Arctic Bioscience - Share Issue/Capital Change 2023

Arctic Bioscience - Share capital increase registered

Reference is made to the stock exchange release published by Arctic Bioscience

7th March 2023 regarding Board approval of share capital increase related to the

exercise of share options and corresponding issuance of new shares in Arctic

Bioscience.

The share capital increase has now been registered with the Norwegian Register

of Business Enterprises. As a result, the new share capital of Arctic Bioscience

has increased from NOK 2 437 571,90 to NOK 2 442 571,90, divided into 24 425 719

shares, each having a nominal value of NOK 0,10.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Act.

For more information, please contact:

Christer L. Valderhaug

CEO

Phone: +47 920 84 601

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing

pharmaceutical and nutraceutical products based on unique bioactive marine

compounds.

The company is developing HRO350 - a novel investigational drug candidate.

HRO350 is being developed for treatment of patients with mild-to-moderate

psoriasis. This is a large patient group in need of new effective medicines with

beneficial safety profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as

well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a team of highly competent people with experience in

developing marine oils and experience from global pharmaceutical companies.

AI assistant